source
- Bausch + Lomb moves dry-eye eye drop to Phase 3 despite missing primary endpoint in Phase 2Bausch + Lomb reported results of a Phase 2 trial of its dual-action dry-eye eye drop, which combines 5% lifitegrast (the active ingredient in Xiidra) with perfluorohexyloctane (PHFO, sold as Miebo…
- Massachusetts biopharma employment slips 3.1% in 2025 as R&D jobs fall, while manufacturing risesA new MassBio industry snapshot shows that total biopharma employment in Massachusetts fell 3.1% in 2025, translating to roughly 3,600 fewer jobs compared with the previous year. The decline was m…